Epithelial cell transcytosis inhibition
Transfer of virus from infected CD4
+ T cells to epithelial cells; movement of virus through epithelial cells
Difficult to standardize and validate (Bomsel, 1997; Tudor et al., 2009) 
Inhibition of DC transfer of virus to CD4 + T cells Transfer of virus to CD4 + T cells
Difficult to standardize and validate (Cavrois et al., 2007; Gummuluru et al., 2002) 
5.
Inhibition of gp120 binding to α4β7 on CD4 + T cells
Ability of antibody to block interaction of gp120 and α4β7-CD4 + T cells
Unknown if α4β7/gp120 interactions are required for transmitted/founder virus infection (Arthos et al., 2008) 6.
Pseudovirus infection inhibition
Env pseudovirus infection of CD4 and CCR5-transduced epithelial cells Reproducible, validated, standardized; antibodies that neutralize and protect in NHP (Li et al., 2005; Schweighardt et al., 2007; Seaman et al., 2007) (Wild et al., 1994) 9.
Cell-to-cell infection inhibition
Transfer of virus from infected to uninfected CD4 + T cells Difficult to standardize and validate (Chen et al., 2007) 10. Antibody adjuvant cellular cytotoxicity NK cell CD16 FcRIII-mediated killing of antibody coated or virusinfected target cells
FcR interactions are important for some mAb virus neutralization. Protective capacity of ADCC antibodies is unknown (Florese et al., 2009; Xiao et al., 2010) 11. Antibody-dependent cellular viral inhibition NK cell and antibody-mediated inhibition of virus growth in PBMC Mechanism of virus suppression can include ADCC, FcR-mediated anti-HIV-1 chemokine release, virus neutralization, and production of other suppressor factors; protective capacity of ADCC antibodies is unknown (Forthal et al., 2005) ADCC, antibody-dependent cellular cytotoxicity; DC, dendritic cells; FcR, Fc receptor; NHP, non-human primate; ADCVI, antibody-dependent cellular viral inhibition 
